MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

NCT06441630 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 251

Last updated 2025-02-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension

Conditions

  • Essential Hypertension

Interventions

DRUG

AD-227A

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUG

AD-227B

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUG

AD-227C

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUG

Placebo of AD-227B

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUG

Placebo of AD-227C

Per Oral, 1 Tablet, Once a day for 8 weeks

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • Chong-Jin Kim · Gangnam CHA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-31
Primary Completion
2025-09-30
Completion
2025-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06441630 on ClinicalTrials.gov